title: [Effect of immune modulation on immunogenic and protective activity of a live plague vaccine].
abstract: OBJECTIVE
  Comparative evaluation of the effect of polyoxidonium and betaleukin on immunogenic and protective activity of a live plague vaccine in model animal experiments.
  
  
  METHODS
  Plague vaccine EV, polyoxidonium, betaleukin, erythrocytic antigenic diagnosticum for determination of F1 antibodies and immune reagents for detection of lymphocytes with F1 receptors (LFR) in adhesive test developed by the authors were used. The experiments were carried out in 12 rabbits and 169 guinea pigs.
  
  
  RESULTS
  Immune modulation accelerated the appearance and disappearance of LFR (early phase) and ensured a more rapid and intensive antibody formation (effector phase). Activation by betaleukin is more pronounced than by polyoxidonium. The more rapid and intensive was the development of early phase, the more effective was antibody response to the vaccine. Immune modulation in the experiment with guinea pigs significantly increased protective activity of the vaccine.
  
  
  CONCLUSIONS
  The use of immune modulators increased immunogenic (in both early and effector phases of antigen-specific response) and protective activity of the EV vaccine. A connection between the acceleration of the first phase of antigen-specific response and general intensity of effector phase of immune response to the EV vaccine was detected. ,
authors: B V
authors: BV
authors: Karal'nik
authors: T S
authors: TS
authors: Ponomareva
authors: P N
authors: PN
authors: Deriabin
authors: T G
authors: TG
authors: Denisova
authors: N N
authors: NN
authors: Mel'nikova
authors: T I
authors: TI
authors: Tugambaev
authors: B B
authors: BB
authors: Atshabar
authors: S B
authors: SB
authors: Zakarian
mesh_terms: D000818:Animals; D000907:Antibodies, Bacterial / Q000096:biosynthesis*; D000942:Antigens, Bacterial / Q000276:immunology; D015870:Gene Expression; D006168:Guinea Pigs; D007111:Immunity, Cellular / Q000187:drug effects; D007114:Immunization; D007074:Immunoglobulin G / Q000096:biosynthesis*; D007155:Immunologic Factors / Q000008:administration & dosage* / Q000276:immunology; D007275:Injections, Intravenous; D053583:Interleukin-1beta / Q000008:administration & dosage* / Q000276:immunology; D010879:Piperazines / Q000008:administration & dosage* / Q000276:immunology; D010930:Plague / Q000097:blood / Q000276:immunology / Q000382:microbiology / Q000517:prevention & control*; D010931:Plague Vaccine / Q000008:administration & dosage* / Q000276:immunology; D011108:Polymers / Q000008:administration & dosage*; D011817:Rabbits; D011948:Receptors, Antigen, T-Cell / Q000235:genetics / Q000276:immunology; D014613:Vaccines, Attenuated; D015010:Yersinia pestis / Q000276:immunology
chemical_list: D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D007074:Immunoglobulin G; D007155:Immunologic Factors; D053583:Interleukin-1beta; D010879:Piperazines; D010931:Plague Vaccine; D011108:Polymers; D011948:Receptors, Antigen, T-Cell; D014613:Vaccines, Attenuated; C540909:azoximer bromide